JP2000159749A5 - - Google Patents

Download PDF

Info

Publication number
JP2000159749A5
JP2000159749A5 JP2000008395A JP2000008395A JP2000159749A5 JP 2000159749 A5 JP2000159749 A5 JP 2000159749A5 JP 2000008395 A JP2000008395 A JP 2000008395A JP 2000008395 A JP2000008395 A JP 2000008395A JP 2000159749 A5 JP2000159749 A5 JP 2000159749A5
Authority
JP
Japan
Prior art keywords
group
embedded image
formula
lower alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000008395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000159749A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2000159749A publication Critical patent/JP2000159749A/ja
Publication of JP2000159749A5 publication Critical patent/JP2000159749A5/ja
Pending legal-status Critical Current

Links

JP2000008395A 1995-12-28 2000-01-17 ベンズイミダゾ―ル誘導体 Pending JP2000159749A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP7-343425 1995-12-28
JP34342595 1995-12-28
JP7/343425 1996-10-08
JP8-287676 1996-10-08
JP8/287676 1996-10-08
JP28767696 1996-10-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP9524201A Division JP3063162B2 (ja) 1995-12-28 1996-12-27 ベンズイミダゾール誘導体

Publications (2)

Publication Number Publication Date
JP2000159749A JP2000159749A (ja) 2000-06-13
JP2000159749A5 true JP2000159749A5 (cg-RX-API-DMAC7.html) 2004-11-11

Family

ID=26556834

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9524201A Expired - Fee Related JP3063162B2 (ja) 1995-12-28 1996-12-27 ベンズイミダゾール誘導体
JP2000008395A Pending JP2000159749A (ja) 1995-12-28 2000-01-17 ベンズイミダゾ―ル誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP9524201A Expired - Fee Related JP3063162B2 (ja) 1995-12-28 1996-12-27 ベンズイミダゾール誘導体

Country Status (16)

Country Link
US (2) US6166219A (cg-RX-API-DMAC7.html)
EP (1) EP0882718B1 (cg-RX-API-DMAC7.html)
JP (2) JP3063162B2 (cg-RX-API-DMAC7.html)
CN (1) CN1211238A (cg-RX-API-DMAC7.html)
AT (1) ATE303365T1 (cg-RX-API-DMAC7.html)
AU (1) AU722514B2 (cg-RX-API-DMAC7.html)
BR (1) BR9612434A (cg-RX-API-DMAC7.html)
DE (1) DE69635135T2 (cg-RX-API-DMAC7.html)
DK (1) DK0882718T3 (cg-RX-API-DMAC7.html)
EA (1) EA002357B1 (cg-RX-API-DMAC7.html)
ES (1) ES2244979T3 (cg-RX-API-DMAC7.html)
HU (1) HUP9900625A3 (cg-RX-API-DMAC7.html)
IL (1) IL124969A (cg-RX-API-DMAC7.html)
NZ (1) NZ324834A (cg-RX-API-DMAC7.html)
TR (1) TR199801249T2 (cg-RX-API-DMAC7.html)
WO (1) WO1997024334A1 (cg-RX-API-DMAC7.html)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
WO1999000372A1 (fr) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
WO1999000359A1 (en) * 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
WO1999051574A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
EP1132087A4 (en) * 1998-11-13 2002-06-26 Fujisawa Pharmaceutical Co MEDICINE AGAINST POLYCYSTIC OVARY SYNDROME
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
BR9916919A (pt) 1998-12-04 2002-01-15 Fujisawa Pharmaceutical Co Compósito de sulfonamida e seu uso
US6869950B1 (en) 1998-12-24 2005-03-22 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CZ20012338A3 (cs) 1998-12-24 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Imidazolové sloučeniny
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
CA2369549A1 (en) * 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
JP2001169268A (ja) 1999-12-14 2001-06-22 Sony Corp 情報提供システム、送信サーバ、情報端末装置、オーサリング装置及び情報提供方法
FR2792635B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique
GB9914255D0 (en) * 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
TR200200161T2 (tr) 1999-07-21 2002-05-21 Fujisawa Pharmaceutical Co. Ltd. Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
CZ20013424A3 (cs) * 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
CN1436080A (zh) * 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp-特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
HUP0300725A3 (en) * 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
KR100863147B1 (ko) * 2001-03-09 2008-10-13 아보트 러보러터리즈 벤즈이미다졸 및 이를 포함하는 성 기능장애 치료용 약제학적 조성물
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
US20020169166A1 (en) * 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
CN1585771A (zh) 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
CA2471760A1 (en) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Preventives/remedies for urinary disturbance
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
SE0301698D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1646614A4 (en) * 2003-07-01 2008-09-10 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP4355917B2 (ja) * 2003-10-29 2009-11-04 信越化学工業株式会社 含窒素有機化合物、レジスト材料及びパターン形成方法
TW200533336A (en) * 2004-03-02 2005-10-16 Fujisawa Pharmaceutical Co Concomitant drugs
CA2560928A1 (en) * 2004-03-29 2005-10-06 Sankyo Company Limited Therapeutic agent for diabetes containing insulin resistance improving agent
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP4953455B2 (ja) * 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター(sarm)として有用な新規なベンゾイミダゾール誘導体
MX2007004525A (es) * 2004-10-12 2007-09-19 Decode Genetics Inc Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
CN101076531A (zh) * 2004-10-12 2007-11-21 解码遗传学公司 用于阻塞性血管疾病的羧酸迫位取代的双环化合物
KR100912146B1 (ko) * 2004-10-27 2009-08-14 에프. 호프만-라 로슈 아게 인돌 또는 벤즈이미다졸 유도체
CA2586179C (en) * 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
US20090137626A1 (en) * 2005-07-12 2009-05-28 Akira Okuno Pharmaceutical Composition Containing PPARgamma Agonist
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1917251B1 (de) 2005-08-21 2013-04-03 Abbott GmbH & Co. KG 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
AU2007214594B2 (en) * 2006-02-13 2010-11-11 F. Hoffmann-La Roche Ag Heterobicyclic sulfonamide derivatives for the treatment of diabetes
US7700618B2 (en) * 2006-03-06 2010-04-20 Pfizer Inc Sulfonyl benzimidazole derivatives
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
CA2652152A1 (en) * 2006-05-16 2007-11-29 Decode Genetics Ehf Process for preparing 7-(acryloyl)indoles
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
EP2099757B1 (en) * 2006-11-16 2014-06-25 Allergan, Inc. Sulfoximines as kinase inhibitors
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8501957B2 (en) * 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
WO2010127246A2 (en) * 2009-04-30 2010-11-04 Burnham Institute For Medical Research Hnf4 modulators and methods of use
JP2013500982A (ja) * 2009-07-30 2013-01-10 エスタス・セラピューティクス・インコーポレイテッド PPARγのベンズイミダゾール誘導体作動薬で神経因性疼痛を治療する方法
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
TWI458714B (zh) * 2009-12-10 2014-11-01 Univ China Medical 苯并咪唑化合物及其用途
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
JP5782234B2 (ja) * 2010-06-16 2015-09-24 チャイナ メディカル ユニヴァーシティーChina Medical University ベンゾイミダゾール化合物およびその使用
EP2397471A1 (en) * 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012174312A2 (en) * 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
EP2847198B1 (en) 2012-05-08 2016-12-14 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror-gamma and the treatment of disease
CN102702006A (zh) * 2012-05-24 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 一种3-氨基-2-硝基苯甲酸乙酯的制备方法
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
WO2014017643A1 (ja) 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN102827084A (zh) * 2012-08-21 2012-12-19 江苏恒祥化工有限责任公司 一种2-(二氯甲基)苯并咪唑的制备方法
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CN104860919B (zh) * 2015-03-26 2017-11-10 天津药物研究院有限公司 含哌啶的苯并咪唑衍生物及其制备方法和用途
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
HK1259107A1 (zh) 2015-12-11 2019-11-22 帝人制药株式会社 氨基唑衍生物
TWI757266B (zh) * 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
CN107311933B (zh) * 2017-06-28 2020-12-22 中国人民解放军军事医学科学院毒物药物研究所 一类苯并咪唑衍生物,及其制备方法和用途
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN108947911B (zh) * 2018-07-03 2022-02-22 中山大学 一种具有抗乙肝病毒活性和抗菌活性的苯并咪唑类化合物及其合成方法和应用
CN111057011B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双(4-氨基苄基)-1-甲基-2-苯基苯并咪唑的制备方法
CN111116484B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双(4-氨基苄基)-1,2二甲基-苯并咪唑的制备方法
CN111116485B (zh) * 2019-12-24 2022-11-11 山西大学 一种5,6-双(4-氨基苄基)-2-三氟甲基-1h-苯并咪唑的制备方法
CN117720472B (zh) * 2022-09-09 2026-06-02 苏州沪云新药研发股份有限公司 一种苯并咪唑类化合物及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE676196C (de) * 1936-08-21 1939-05-30 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Imidazolverbindungen
US3152142A (en) * 1962-05-24 1964-10-06 Dow Chemical Co Benzimidazole compounds
US4243813A (en) 1974-07-01 1981-01-06 Eli Lilly And Company Substituted 1-sulfonylbenzimidazoles
FR2291749A1 (fr) * 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
JPS51133267A (en) * 1975-05-08 1976-11-18 Lilly Co Eli Substituted 11sulphonyl benzimidazole
US4179505A (en) * 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4243806A (en) * 1979-06-13 1981-01-06 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
GB2053215B (en) * 1979-06-25 1983-04-07 May & Baker Ltd Benzimidazole derivatives
JPS625966A (ja) * 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
JPH03218362A (ja) * 1988-12-22 1991-09-25 Yamanouchi Pharmaceut Co Ltd 4,5,6,7―テトラヒドロベンズイミダゾール誘導体及びそれを含有する医薬
JPH05507469A (ja) * 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
RU1836357C (ru) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5602127A (en) * 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
DE4224133A1 (de) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9121776D0 (en) * 1991-10-14 1991-11-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives and process for preparation thereof
DE4237557A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
JPH0853424A (ja) * 1994-08-11 1996-02-27 Kureha Chem Ind Co Ltd ベンズイミダゾールスルホン酸アミド誘導体
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JPH11154208A (ja) 1997-11-21 1999-06-08 Mitsubishi Electric Corp Icカード及びその製造方法

Similar Documents

Publication Publication Date Title
JP2815617B2 (ja) 縮合ピリミジン誘導体およびその製造方法
CN1319529C (zh) 作为大麻素-cb1受体配体的1h-1,2,4-三唑-3-酰胺衍生物
EP1372656B1 (en) Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
CN1247583C (zh) 三唑并[4,5-d]嘧啶化合物的新晶形和非晶形
CN1187367C (zh) 具有麻醉剂活性的3α-羟基-3β-甲氧基甲基-21-杂环取代的类固醇
FI88504B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-benzyl-1-(2h)-ftalazinonderivat
CN110997653B (zh) 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
CN1346349A (zh) 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物
US9452169B2 (en) Substituted diketopiperazines and their use as oxytocin antagonists
SK4562002A3 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
CN1333767A (zh) 作为消炎剂的芳香族杂环化合物
WO2000012487A1 (en) Pyrimidine derivatives
CN1065460A (zh) 衍生于苯并咪唑的新的非镇静抗组胺剂
CN105051031B (zh) 1‑([1,3]二氧戊环‑4‑基甲基)‑1h‑吡唑‑3‑胺的制备方法
JPWO2016204153A1 (ja) 置換ジヒドロピロロピラゾール誘導体
JP2002526410A5 (cg-RX-API-DMAC7.html)
JP3204456B2 (ja) 2,7―置換オクタヒドロ―ピロロ[1,2―a]ピラジン誘導体
WO1993013739A2 (en) Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues
CN1085981C (zh) 烟酸酯化合物及其盐,它们的制法及含有该化合物的药物组合物
JPS5831351B2 (ja) 6−フエニル−S−トリアゾロ−(4,3−a)−ピリド−(2,3−f)−(1,4)−ジアゼピン及びその製造方法
JPH11506425A (ja) エチニルチアゾール誘導体
JPS6222771A (ja) 5−置換−6−アミノピリミジン誘導体、組成物および使用
CN1432013A (zh) 咪唑衍生物或其盐以及含有该衍生物或其盐的药物
JP4444492B2 (ja) 2−{3−[4−(2−t−ブチル−6−トリフルオロメチルピリジン−4−イル)ピペラジン−1−イル]プロピルメルカプト}ピリミジン−4−オル−フマレート
WO2004083211A1 (ja) ピラゾロピリミジン化合物及びその用途